Noncardiac chest pain (NCCP) is defined as recurring, angina-like, retrosternal chest pain of noncardiac origin. Although patients with NCCP have excellent long-term prognosis, most suffer persistently from their symptoms. Several pathophysiological mechanisms have been suggested, including gastroesophageal reflux disease (GERD), esophageal motility disorder, esophageal hypersensitivity, and psychological comorbidity. Among them, GERD is the most common cause of NCCP. Therefore, GERD should first be considered as the underlying cause of symptoms in patients with NCCP. Empirical proton pump inhibitor (PPI) treatment with a preferably double dose for more than 2 months could be cost-effective. PPI test can also be used for diagnosis of GERD-related NCCP, but it should be considered for patients with NCCP occurring at least weekly and its duration should be at least 2 weeks. However, upper endoscopy and esophageal pH monitoring are necessary when the diagnosis of GERD is uncertain. Esophageal impedance-pH monitoring could further improve the diagnostic yield. Patients with GERD-related NCCP should preferably be treated with a double dose PPI until symptoms remit (may require more than 2 months of therapy for optimal symptom control), followed by dose tapering to determine the lowest PPI dose that can control symptoms. However, treatment of patients with non-GERD−related NCCP is challenging. An empirical treatment of antidepressants could be considered. If there are specific esophageal motility disorders, smooth muscle relaxants or endoscopic treatment may be considered in selected cases. If none of these traditional treatments is effective, a psychology consultation for cognitive behavioral therapy should be considered. (Korean J Gastroenterol 2015;65:76-84) Key Words: Diagnosis; Gastroesophageal reflux disease; Noncardiac chest pain (NCCP); Therapy CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Noncardiac chest pain (NCCP) is defined as recurring, angina-like, retrosternal chest pain of noncardiac origin. 1 In the diagnostic evaluation of chest pain, exclusion of coronary artery disease (CAD) is of great importance. 2 However, as a patient's history and characteristics do not reliably distinguish between cardiac and noncardiac causes of chest pain, 3 a reasonable cardiac evaluation is required. 4 Decisions regarding which tests to pursue should be made by the treating cardiologist. 1 According to data from a chest pain clinic in the United Kingdom, nearly half of patients with NCCP nevertheless are not convinced by their negative cardiac diagnosis and experience ongoing chest pain. 5 Epidemiologic data of NCCP are limited. In a recent meta-analysis including 16 studies from 14 separate populations, pooled prevalence of NCCP was 13% (95% CI, 9-16%). 6 However, significant heterogeneity was present among reported studies. In a Korean population study (n=1,417), 7 the prevalence of chest pain was 7.9%. Patients with NCCP report poor quality of life, 8, 9 while increased mortality is unusual. [10] [11] [12] [13] Cohort studies show that many patients with NCCP (67-74%) continue to experience symptoms, [11] [12] [13] resulting in high healthcare cost. 14 Despite this significant burden, the pathophysiological mechanisms behind symptom generation remain to be elucidated. However, advances in understanding NCCP have been made in the past decade. This review describes the recent evidence regarding diagnosis and treatment in patients with NCCP; only esophageal-related causes for NCCP are covered here.
DIAGNOSIS
Because the morbidity and mortality of CAD far exceeds that of esophageal-related causes of NCCP, further esophageal workup is warranted only after cardiac disease has been ruled out. 15 
GERD is the most common cause of NCCP (GERDrelated NCCP)
In a prospective, double-blind, randomized clinical trial (RCT) of patients with NCCP and GERD documented by 24-hour pH monitoring, patients on omeprazole achieved greater overall symptom improvement when compared with placebo (81% vs. 6%, p=0.001). 16 A recent systematic review including 6 RCTs also reported similar results. 17 The therapeutic gain of ＞50% improvement with proton pump inhibitors (PPIs) relative to placebo was 56-85% in NCCP patients with objective evidence of GERD and 0-17% in those without objective evidence of GERD.
Epidemiologic study data support the association between NCCP and GERD. Markedly higher prevalence of NCCP was observed for subjects who also reported GERD (OR, 4.71; 95% CI, 3.32-6.70) and increased according to frequency of GERD symptoms. 6 Similar results were also reported in a Korean study. 7 GERD was reported in 61.6% of subjects with chest pain. According to presence of GERD the prevalence of chest pain was markedly different: 3.6% in subjects with no GERD symptoms, 28.8% in those with occasional GERD symptoms, and 44.0% in those with frequent GERD symptoms.
Therefore GERD should be considered first as the underlying cause of symptoms in patients with NCCP.
Upper endoscopic evaluation is necessary in patients with NCCP
In the absence of a gold standard for the diagnosis of GERD, upper endoscopy provides objective evidence of GERD. The presence of reflux esophagitis on endoscopy could confirm the diagnosis of GERD-related NCCP. In addition, in Korea, with a high prevalence of peptic ulcer disease and gastric cancer, the coexistence of GERD-related NCCP with other gastric diseases should also be considered. 18 In addition, endoscopy in patients with alarm symptoms results in a significant yield of cancer and serious benign diseases such as peptic ulcer, stricture, and severe esophagitis.
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Thus upper endoscopy should precede other testing in the evaluation of NCCP.
However, the prevalence of esophageal mucosal abnormalities consistent with GERD is lower in patients with NCCP compared with that observed in patients with GERD. 26, 27 In a study performing 24-hour impedance-pH monitoring twice on and off PPI in patients with PPI-refractory GERD, 27 the number of heartburn episodes related to reflux decreased on PPI compared with off PPI, while the numbers of chest pain episodes and regurgitation were not different.
In another study with PPI-refractory GERD patients, 28 the number of weakly acidic refluxes was abnormal in all patients, whereas the number of acid and weakly alkaline refluxes was normal in the vast majority of patients. Thus, both acid and nonacid refluxes may be involved in the pathogenesis of NCCP. We also showed that evaluation of esophageal bolus exposure by 24-hour impedance-pH monitoring improved detection of GERD in patients with NCCP. 29 Thus impedance-pH monitoring is better than pH monitoring alone in the evaluation of NCCP. In patients with PPI-refractory NCCP impedance-pH monitoring could be performed on PPI therapy, while in patients requiring objective evidence of GERD it should be performed off PPI therapy. However, impedance-pH monitoring off PPI seems to offer the best chance to assess a relationship between symptoms and reflux episodes. 27 
PPI test can be used to confirm the diagnosis of GERD-related NCCP
Given the high prevalence of GERD in patients with NCCP and excellent efficacy of PPI in them, 6, 17 empirical PPI treatment for 2-3 months could be cost-effective in management of NCCP. In addition, NCCP patients with typical reflux symptoms are more likely to have GERD-related NCCP than those without typical reflux symptoms. 30 Accordingly, empirical PPI treatment is a cost-effective diagnostic strategy in NCCP patients with typical reflux symptoms.
In contrast to empirical PPI treatment, a short course (1-2 weeks) of high-dose PPI trial (PPI test) could confirm the diagnosis of GERD in patients with NCCP. 23 Several trials using dif- with NCCP occurring at least weekly, and its duration should be at least 2 weeks.
Esophageal manometry could be helpful in the evaluation of NCCP
Esophageal manometry is the best tool for detection of abnormal esophageal motor function. 37 In patients with NCCP, 30% have abnormal esophageal motility on manometry. 38, 39 However, the relationship between these abnormal motilities and chest pain remains unclear and specific esophageal motility disorders such as achalasia and nutcracker esophagus, and diffuse esophageal spasm are found in only a minority of patients. 30, 38, 39 Likewise, the American Gastroenterological Association guidelines on esophageal manometry state that manometry is not indicated as the initial test for chest pain because of the low specificity of the findings and the low likelihood of detecting a clinically significant motility disorder. 37 However, manometry could detect achalasia, jackhammer esophagus or nutcracker esophagus, and distal esophageal spasm that could explain the patient's chest pain. [40] [41] [42] [43] [44] [45] 
TREATMENT
Because it is a heterogeneous disorder treatment of NCCP has been very challenging. Several pathophysiological mechanisms have been suggested, including GERD, esophageal motility disorder, esophageal hypersensitivity, and psychological comorbidity. 1, 47 Thus, treatment of patients with NCCP should target the specific underlying mechanism responsible for patient's symptoms.
GERD-related NCCP
GERD is the most common cause of NCCP, and PPIs are the most effective, antisecretory medications that are currently In conclusion, patients with GERD-related NCCP should preferably be treated with a double dose PPI until symptoms remit, followed by dose tapering to determine the lowest PPI dose that can control symptoms. 4 As with other extra-esophageal manifestations of GERD, NCCP patients may require more than 2 months of therapy for optimal symptom control. nutcracker esophagus when compared with placebo. 53, 54 However, in a study involving 8 patients with diffuse esophageal spasm, the effect of diltiazem was not significant. 55 In the treatment of NCCP, calcium channel blockers are limited by a transient esophageal motor effect and side effects such as hypotension, bradycardia, and edema. 4, 56 Although several open-label studies have reported that nitrates improve symptoms and esophageal motility patterns in patients with chest pain and esophageal dysmotility, they have been limited by a small number of patients and inconsistent results in regard to drug efficacy. [57] [58] [59] [60] [61] Sildenafil, a potent selective inhibitor of cyclic guanosine monophosphate -specific phosphodiesterase type 5, has been shown to improve esophageal motility in patients with nutcracker esophagus or hypertensive LES. 62, 63 However, thus far, no studies specifically addressing NCCP patients have been reported.
Improvements of esophageal contraction have been reported in patients with nutcracker who were treated with the anticholinergic agents, cimetropium bromide (10 mg intravenously) 64 and atropine (10 g/kg intravenously). 65 However, clinical data regarding the efficacy of anticholinergic agents (especially of an oral formulation) on symptom improvement in NCCP patients have yet to be reported.
Botulinum toxin injection at the gastroesophageal junction leads to 50% reduction of chest pain episodes in 72% of patients with spastic esophageal motility disorders whose major complaint is chest pain for a mean duration of 7. 
2) Esophageal visceral hypersensitivity
Visceral hypersensitivity is a key underlying mechanism of patients with non-GERD−related NCCP, regardless of whether esophageal motility disorder is present. Patients with chest pain and nutcracker esophagus were more likely to experience pain (9/10) than the control (2/12) by stepwise esophageal balloon distensions. 70 When esophageal balloon distension test was performed after excluding GERD and achalasia from 332 NCCP patients, hypersensitivity was found in 71% (128/181) of the remaining patients. 21 When esophageal motility disorders other than achalasia were also ex- In a recent systematic review of published trials regarding effects of antidepressants on non-GERD−related NCCP, 74 6
RCTs involving 251 patients were evaluated and drugs included were selective serotonin reuptake inhibitors (paroxe- 15%, p=0.02), and imipramine (52% vs. 1%, p=0.03). The improvement in chest pain symptoms was independent of improvement in depression scores. Clinical global improvement was also noted in patients on venlafaxine, sertraline, paroxetine, and trazodone. In a recent study, 81 combination of pain coping skill training plus sertraline showed the highest response, compared to either alone or placebo, in patients with NCCP. However, adverse effects were more common in the antidepressants treatment group (33-75%) than in the placebo (12-65%). 75, [77] [78] [79] [80] Adverse effects were also reason for discontinuation of trials in 53% of the treatment groups compared with 29% of the placebo group. 74 In addition, clinical data regarding the efficacy of antidepressants After an open-label pilot trial, 82 an RCT showed that theophylline (200 mg by mouth, twice a day), an adenosine receptor antagonist, for 4 weeks improved pain in patients with chest pain and esophageal hypersensitivity by relaxing the esophageal wall and decreasing hypersensitivity. 83 However, the study was small (n=19) and no further studies supporting the results have been reported.
3) Psychosomatic treatment
Treatment of patients with NCCP refractory to pharmacotherapy is challenging. Psychological comorbidity including panic disorder, anxiety, major depression, and more has been shown to be common in patients with NCCP and affects up to 75%, 1 suggesting that treatment of the underlying psychological factors may result in better patient outcomes.
Because cognitive behavioral therapy (CBT) has been reported to be useful for treatment of panic disorders, it has been proposed that it may be useful in NCCP. 2 The purpose of CBT is to educate patients in order to correct the misattributions regarding chest pain as being harmful. Several studies have demonstrated good efficacy of CBT in patients with chest pain. 2, 4, 84, 85 In an RCT, patients who received CBT for 4-12 weeks had significantly better chest pain control (48%) than those in the control group (12%) at a 12-month follow-up. 86 In another study involving patients with persisting NCCP after negative cardiac evaluation, 12 sessions of CBT significantly decreased the pain severity and the number of pain-free days as compared to control, at 3 and 6 months. 87 However, in another RCT including patients with NCCP and benign palpitation, chest pain was not improved with three sessions of CBT. 88 Hypnotherapy showed greater improvements in chest pain, pain intensity, and overall well-being, but not in pain frequency reduction in an RCT with 28 NCCP patients. 89 In conclusion, treatment of patients with NCCP refractory to pharmacologic therapy could be considered for CBT at the experienced center.
CONCLUSION
GERD appears to be the most common cause of NCCP.
Therefore GERD should first be considered as the underlying cause of symptoms in patients with NCCP. Empirical PPI treatment with a preferably double dose for more than 2 months could be cost-effective in patients with concomitant typical reflux symptoms. PPI test can be used for diagnosis of GERD-related NCCP but it should be considered for patients with NCCP occurring at least weekly and its duration should be at least 2 weeks. Upper endoscopy and esophageal pH monitoring provide objective evidence of GERD, and thus are necessary when the diagnosis of GERD is uncertain.
Esophageal impedance-pH monitoring could further improve the diagnostic yield, particularly in patients with PPI-refractory NCCP.
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Treatment of patients with NCCP should target the specific underlying mechanism responsible for patient's symptoms.
Patients with GERD-related NCCP should preferably be treated with a double dose PPI until symptoms remit (may require more than 2 months of therapy for optimal symptom control), followed by dose tapering to determine the lowest PPI dose that can control symptoms. In patients with non-GERD− related NCCP, an empirical treatment of antidepressants (preferably venlafaxine, sertraline, and imipramine) should be considered. If specific esophageal motility disorders such as jackhammer esophagus or nutcracker esophagus and distal esophageal spasm are detected, smooth muscle relaxants or endoscopic treatment may be considered in selected cases. If none of these treatments is helpful, a psychology consultation is necessary for psychosomatic treatment such as CBT. Our suggested algorithm for management of patients with NCCP is shown in Fig. 1 .
